Cognition Therapeutics, Inc. CGTX 深 沪
等待开盘 05-21 09:30:00 美东时间
1.24
+0.130
+11.71%
华盛通- 最 高1.25
- 今 开1.12
- 成交量 79.27万股
- 最 低 1.09
- 昨 收 1.11
- 总市值 1.11亿
- 52周最高 3.83
- 市盈率 静 --
- 换手率 0.89%
- 52周最低 0.24
- 委 比 -68.22%
- 总股本 8949.80万
- 历史最高 13.80
- 量 比 2.58
- 振 幅 14.41%
- 历史最低 0.2223
- 每 手 1
- 风险率 0.57%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Cognition Therapeutics Announces Second Philanthropic Donation From A Participant In The Ongoing Expanded Access Program For People With Dementia With Lewy Bodies
The ongoing EAP has been extended to provide two years of treatment for participants, thanks to a generous new donation from Mr. Jeffrey Pechter, founding partner of Mindful Capital in Delray Beach, FL.The open-label EAP
05-14 19:34
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Cyclerion Therapeutics (NASDAQ:CYCN) shares rose 307.1% to $6.31 durin...
04-02 01:06
Cognition Therapeutics shares are trading lower. The company reported Q4 financial results.
Cognition Therapeutics shares are trading lower. The company reported Q4 financ...
03-27 23:53
Cognition Therapeutics Q4 EPS $(0.01) Beats $(0.05) Estimate
Cognition Therapeutics (NASDAQ:CGTX) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.05) by 80 percent. This is a 94.12 percent increase over losses of $(0.17) per share
03-26 19:32
Earnings Scheduled For March 26, 2026
Companies Reporting Before The Bell • ProShares UltraShort Russell2000 (NYSE:TW...
03-26 19:11
Cognition Therapeutics Presents Analysis From Phase 2 COG1201 SHIMMER Study Of Zervimesine In Dementia With Lewy Bodies At AD/PD 2026 Alzheimer's & Parkinson's Diseases Conference
Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ:CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, presented an analysis from the Phase 2 COG1201 SHIMMER study
03-17 19:35
Cognition Therapeutics Extends Duration Of Expanded Access Program For Dementia With Lewy Bodies
Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, has extended the duration of the expanded access program
02-05 20:40
Cognition Therapeutics Meets With FDA to Plan Mid-Stage Trial for Lewy Body Dementia Drug
Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ:CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, conducted a Type C meeting with the U.S. Food and Drug
01-27 20:37
Cognition Therapeutics Study On Phase 2 Trial Of Zervimesine In Patients With Mild-to-Moderate Dementia With Lewy Bodies Meets Primary Endpoint Of Safety, Tolerability
Cognition Therapeutics, Inc. (NASDAQ: CGTX), today announced that a manuscript entitled, "Phase 2 Study of Zervimesine (CT1812) in Participants with Mild-to-Moderate Dementia with Lewy Bodies (DLB)" (doi:
01-06 20:36
Cognition Therapeutics Presented Plans For Registrational Program For Zervimesine In Mild-To-Moderate Alzheimer's Disease
Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, presented plans for a registrational program for zervimesine in
2025-12-01 20:40
